Share this post on:

Product Name :
pacritinib citrate

Search keywords :
CDK2

drugId :
null

Target Vo:
Tyrosine-protein kinase JAK2

Target Vo Short Name :
JAK2

Moa_Name:
Tyrosine-protein kinase JAK2 inhibitors

First Approval Country :
United States

First Approval Date Filter:
2022

Origin Company_Name :
Concert

Active Company_Name :
Baxter International Inc

Active Indication_Name:
Primary Myelofibrosis

In Active Indication_Name:
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Glucose Transporter GLUT1 Antibody
Catalase Antibody (YA552)
RSK1 p90 Antibody (YA088): RSK1 p90 Antibody (YA088) is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to RSK1 p90. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Share this post on:

Author: Interleukin Related